- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06413602
The Synergistic Effects of AIH and FES in Persons With MS
Exploring the Synergistic Effects of AIH and FES in Persons With MS
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
NMES: NMES refers to the application of mild electrical stimulation and is often used as an assistive technology for foot drop in MS and other neurologic conditions. The NMES-induced improvement in motor performance appears to be mediated primarily by an increase in corticomotoneuronal excitability. A single session of NMES applied over a peripheral nerve, has been shown to transiently increase net corticospinal excitability (increased MEP amplitude) in both able-bodied individuals and in people with neurological conditions.
AIH: AIH involves breathing brief bouts of low levels of oxygen. Research has found AIH to be a safe and effective intervention resulting in increased ankle strength in people with MS. While AIH has shown potential in enhancing neuroplasticity in people with spinal cord injury (SCI), it has yet to be studied extensively in MS. Preliminary research in the MS population demonstrates that a single session of AIH enhances motor output, increasing voluntary muscle strength by as much as 15-20% within 60 minutes. Over the past decade, studies have found AIH can rapidly enhance neural plasticity in persons with incomplete SCI. AIH activates the serotonergic pathway, leading to increased activity of serotonin receptors and the synthesis of plasticity-related proteins. This plasticity is manifested by a rapid increase in voluntary muscle strength, emerging within 60-90 minutes.
In this study, we will examine how NMES, which has been shown to affect cortical excitability, and AIH, which has been shown to affect corticospinal plasticity, may synergistically enhance corticospinal excitability in people with relapsing form of MS. Foot drop is a common symptom in the diagnosis of MS where the inability to maintain active dorsiflexion during the swing phase of the gait cycle affects walking efficiency, instability, and falls. Seminal studies show that individuals with MS retain the ability to express plasticity even at higher levels of disease burden. This indicates that strategies targeting neuroplasticity can be used to enhance functional recovery and limit the impact of MS disability. We will conduct a randomized, blinded, placebo-controlled, cross-over study in 20 MS patients with established motor deficits and controlled relapse activity.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rachel A Kravitt, OTD, OTR/L
- Phone Number: (312)238-3947
- Email: rkravitt@sralab.org
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Shirley Ryan AbilityLab
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of relapsing form of MS
- Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5
- Motor Functional Systems Score (FSS) between 2-4
- Relapse free for at least 1 year
- Age ≥18 years and ≤75 years
- Safe to participate in MRI (as indicated via the SRALab MRI questionnaire)
- No change in Dalfampridine dose at least 2 months prior to enrollment
Exclusion Criteria:
- Uncontrolled hypertension or hypotension (outside 140/90 and 90/60 mmHg)
- History of epilepsy or seizures
- Uncontrolled medical problems affecting the lungs (pulmonary diseases including chronic obstructive pulmonary disease), the heart (cardiovascular diseases) or the musculoskeletal system (orthopedic diseases)
- Premorbid, ongoing major depression or psychosis, altered cognitive status
- History of stroke
- Metal in head (e.g., surgical clips, shrapnel)
- Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold such as antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants
- Surgery to the head
- Any non-MS related neurological diseases
- Illnesses that may have caused brain injury
- Unexplained frequent or severe headaches
- Pregnancy in females
- Implanted devices (e.g., pacemakers, medical pumps, brain stimulators)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AIH alone
Participants will undergo 30 minutes of AIH.
|
During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention.
The AIH intervention involves alternating breathing cycles.
One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration.
This cycle is repeated 15 times in one session.
Blood oxygen and heart rate are monitored throughout.
Other Names:
|
Experimental: NMES alone
Participants will undergo repetitive common peroneal nerve stimulation for up to 30 minutes.
|
During NMES, participants will receive electrical stimulation to the common peroneal nerve.
Stimulation will be done with a 50% duty cycle, duration of 0.5-1ms for each pulse and a frequency 25-40 Hz.
The stimulus intensity will be adjusted to produce approximately 50% of the maximum M-wave (compound muscle action potential) for each participant.
Other Names:
|
Experimental: Combined AIH and NMES
Participants will undergo 30 minutes of AIH.
Immediately following, participants will undergo NMES for up to 30 minutes.
|
During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention.
The AIH intervention involves alternating breathing cycles.
One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration.
This cycle is repeated 15 times in one session.
Blood oxygen and heart rate are monitored throughout.
Other Names:
During NMES, participants will receive electrical stimulation to the common peroneal nerve.
Stimulation will be done with a 50% duty cycle, duration of 0.5-1ms for each pulse and a frequency 25-40 Hz.
The stimulus intensity will be adjusted to produce approximately 50% of the maximum M-wave (compound muscle action potential) for each participant.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motor Evoked Potentials (MEPs) in Ankle Dorsiflexors
Time Frame: Immediately prior to and within 60 minutes after the intervention.
|
The MEPs will be elicited by Transcranial Magnetic Stimulation (TMS), a procedure that uses magnetic fields to stimulate nerve cells in the brain.
|
Immediately prior to and within 60 minutes after the intervention.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ankle Dorsiflexion Torque
Time Frame: Immediately prior to and within 60 minutes after the intervention.
|
Maximal volitional ankle dorsiflexion flexion torque will be measured using a strength testing dynamometer (Biodex System 4).
|
Immediately prior to and within 60 minutes after the intervention.
|
Ankle Dorsiflexion EMG
Time Frame: Immediately prior to and within 60 minutes after the intervention.
|
While measuring ankle dorsiflexion torque, we will also record surface electromyography (EMG) from the tibialis anterior muscle during each contraction.
|
Immediately prior to and within 60 minutes after the intervention.
|
Symbol Digit Modalities Test
Time Frame: Immediately prior to and within 60 minutes after the intervention.
|
A neurocognitive test that requires individuals to pair specific numbers with given geometric figures within 90 seconds.
Both written and oral format will be administered, and scores will be calculated by totaling the number of correct answers for each section.
|
Immediately prior to and within 60 minutes after the intervention.
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Disease Attributes
- Chronic Disease
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
- Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
Other Study ID Numbers
- STU00221027
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
Clinical Trials on Acute Intermittent Hypoxia
-
University of Colorado, BoulderMedical University of South Carolina; University of Colorado, Denver; Eunice...Enrolling by invitationIncomplete Spinal Cord InjuryUnited States
-
Northwestern UniversityRecruitingHealthy Brain PerfusionUnited States
-
Shirley Ryan AbilityLabUnknownSpinal Cord InjuriesUnited States
-
Shirley Ryan AbilityLabEnrolling by invitation
-
Shirley Ryan AbilityLabEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingMultiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis-Relapsing-RemittingUnited States
-
Shirley Ryan AbilityLabNational Multiple Sclerosis SocietyNot yet recruitingMultiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary ProgressiveUnited States
-
University of FloridaCompletedNeuromuscular Diseases | Amyotrophic Lateral Sclerosis (ALS)United States
-
University of FloridaU.S. Army Medical Research Acquisition ActivityRecruiting
-
Shirley Ryan AbilityLabNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting
-
Xinhua Hospital, Shanghai Jiao Tong University...Not yet recruiting